Pharmaceuticals maker Eli Lilly & Co today caught some continued bullish commentary from analysts at Bank of America/Merrill Lynch.
The firm reiterated its “Buy” rating on LLY and boosted its price target to $52. That new target suggests a 16% upside to the stock’s Tuesday closing price of $44.71. Bank of America/Merrill Lynch also raised its earnings estimates for the company, citing the strong potential for Ramucirumab to be a successful cancer treatment.
PHASE 3Ramucirumab is being investigated in clinical trials for the treatment of breast cancer, gastric cancer, bladder cancer, urethra cancer, ureter cancer, renal pelvis carcinoma, prostate cancer, ovarian cancer, and glioblastoma multiforme.
Aucun commentaire:
Enregistrer un commentaire